CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL) (NCT01134575)
The goal of this clinical research study is to learn if CMC-544 (Inotuzumab Ozogamycin) given alone, and possibly given in combination with rituximab, can help to control the disease in patients with ALL. The safety of the study drug(s) will also be studied.
- Condition: Leukemia
- Phase: I
- Estimated Enrollment: 90
- Start: June 2010
- Estimated Primary Completion: June 2017
- Last verified: April 2105
Last Editorial review: July 31, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.